Skip to main content
U.S. flag

An official website of the United States government

Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice

Bibliographic

Year of Publication:
2000
Contact PI Name:
Cynthia A. Lemere
Contact PI Affiliation:
Center for Neurologic Diseases, Harvard Institutes of Medicine, Boston, Massachusetts, USA
Co-Authors:
R. Maron, E.T. Spooner, T.J. Grenfell, C. Mori, R. Desai, W.W. Hancock, H.L. Weiner, D.J. Selkoe
Primary Reference (PubMED ID):
Funding Source:
Not Reported
Study Goal and Principal Findings:

Amyloid accumulation and accompanying inflammation—including both the activation of glial cells and the accrual of inflammatory proteins, such as complement, cytokines, and acute phase proteins play key roles in the pathogenesis of Alzheimer’s disease (AD). Mucosal administration of proteins implicated in a disease can decrease organ-specific inflammatory processes in a number of animal models of autoimmune disorders, including those affecting the nervous system, principally by inducing antiinflammatory IL-4/IL-10 (Th2) and TGFβ immune responses in mucosal lymphoid tissue that then act systemically. For example, oral or nasal administration of myelin basic protein (MBP) or the acetylcholine receptor can suppress experimental autoimmune encephalomyelitis (EAE) and experimental myasthenia gravis, respectively. In an effort to reduce the inflammation associated with Aβ deposition via mucosal tolerance, we tested the effects of nasal or oral administration of Aβ1–40 peptide and a control protein, myelin basic protein (MBP), by treating 52 PD-APP transgenic mice, an animal model with certain key features of AD, on a weekly basis for seven months (ages 5 to 12 months). Doses were chosen based on preliminary nasal and oral studies in nontransgenic mice. Treatment groups included (1) untreated (n = 7); (2) MBP oral, 500 μg (n = 5); (3) MBP nasal, 50 μg (n = 6); (4) Aβ oral, 10 μg (n = 9); (5) Aβ oral, 100 μg (n = 9); (6) Aβ nasal, 5 μg (n = 7); and (7) Aβ nasal, 25 μg (n = 9). During the first week, mice were fed five times or nasally treated three times on consecutive days. Thereafter, mice were fed or nasally treated each week for seven months and then sacrificed. The brain from each mouse was removed and divided in half along the sagittal midline. One hemisphere was formalin fixed and embedded in paraffin for immunohistochemical analysis. Of the contralateral hemispheres, half were snap frozen for biochemical analysis; the other half were embedded sagittally in OCT and snap frozen for  cryosectioning and immunohistochemistry.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Biologic - Immunotherapy(active)
Therapeutic Agent:
beta Amyloid Peptide 1-40
Therapeutic Target:
beta Amyloid Peptide

Animal Model

Model Information:
Species:
Mouse
Model Type:
APP
Strain/Genetic Background:
Not Reported

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Histopathology
Activated Astrocytes
Activated Microglia
beta Amyloid Deposits
beta Amyloid Load
Dystrophic Neurites
Biochemical
Brain-beta Amyloid Peptide 40
Brain-beta Amyloid Peptide 42
Immunochemistry
Activated Astrocytes
Activated Microglia
Brain-beta Amyloid Deposits
Interleukin 4 (IL-4)
Interleukin 10 (IL-10)
Tumor Growth Factor beta (TGF beta)
Immunology
Anti-beta Amyloid Antibody Titers
Anti-beta Amyloid Antibody Isotypes
Anti-beta Amyloid IgG Production
Antibody Target Specificity
Epitope Mapping
Humoral Response
Pharmacokinetics
Antibody Concentration-Serum
Pharmacodynamics
Target Engagement (Reduction beta Amyloid Deposits)